Financial relationships between physicians and the health care industry sometimes lead to conflicts of interest and need to be properly managed. Using the Open Payments Database between 2013 and 2021, this cross-sectional analysis examined the industry payments made to physicians whose primary specialty was pediatrics. Descriptive analyses were performed for the payment data overall and other pediatrician demographics. Of 99 764 eligible pediatricians, 59 984 (60.1%) received a total of $297 million (12.8%) in general and $2 billion in research payments over the 9 years. Median 9-year per-physician payments were $288 (interquartile range [IQR]: $88-$958) in general and $65 343 (IQR: $16 763-$255 208) in research payments. Male pediatricians were 1.06 (95% CI: 1.05-1.09, P < .001) and 1.56 (95% CI: 1.49-1.65, P < .001) times more likely to receive general and associated research payments than female pediatricians, respectively. The number of pediatricians receiving general payments annually decreased by 1.5% (95% CI: −1.7% to −1.4%, P < .001).
FickweilerFFickweilerWUrbachE.Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review. BMJ Open. 2017;7(9):e016408. doi:10.1136/bmjopen-2017-016408.
2.
WilsonJM.Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab. 2009;96(4):151-157. doi:10.1016/j.ymgme.2008.12.016.
3.
JohnsonLStrickerRB.Attorney general forces Infectious Diseases Society of America to redo Lyme guidelines due to flawed development process. J Med Ethics. 2009;35(5):283-288. doi:10.1136/jme.2008.026526.
4.
EichackerPQNatansonCDannerRL.Surviving sepsis—practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med. 2006;355(16):1640-1642. doi:10.1056/NEJMp068197.
5.
Pham-KanterG.Act II of the Sunshine Act. PLoS MED. 2014;11(11):e1001754. doi:10.1371/journal.pmed.1001754.
6.
CampbellEGGruenRLMountfordJMillerLGClearyPDBlumenthalD.A national survey of physician-industry relationships. N Engl J Med. 2007;356(17):1742-1750. doi:10.1056/NEJMsa064508.
7.
MarshallDCJacksonMEHattangadi-GluthJA.Disclosure of industry payments to physicians: an epidemiologic analysis of early data from the open payments program. Mayo Clin Proc. 2016;91(1):84-96. doi:10.1016/j.mayocp.2015.10.016.
8.
TringaleKRMarshallDMackeyTKConnorMMurphyJDHattangadi-GluthJA.Types and distribution of payments from industry to physicians in 2015. JAMA. 2017;317(17):1774-1784. doi:10.1001/jama.2017.3091.
9.
TringaleKRHattangadi-GluthJA.Types and distributions of biomedical industry payments to men and women physicians by specialty, 2015. JAMA Intern Med. 2018;178(3):421-423. doi:10.1001/jamainternmed.2017.7445.
10.
KarasDJBandariJBrowningDNJacobsBLDaviesBJ.Payments to pediatricians in the Sunshine Act. Clin Pediatr. 2017;56(8):723-728. doi:10.1177/0009922816670981.
11.
ParikhKFleischmanWAgrawalS.Industry relationships with pediatricians: findings from the open payments Sunshine Act. Pediatrics. 2016;137(6):e20154440. doi:10.1542/peds.2015-4440.
12.
EloyJABobianMSviderPF, et al. Association of gender with financial relationships between industry and academic otolaryngologists. JAMA Otolaryngol Head Neck Surg. 2017;143(8):796-802. doi:10.1001/jamaoto.2017.0276.
13.
MurayamaAKugoHSaitoYSaitoHTanimotoTOzakiA.A 9-year investigation of healthcare industry payments to pulmonologists in the United States. Ann Am Thorac Soc. 2023;20(9):1283-1292. doi:10.1513/AnnalsATS.202209-827OC.
KusumiEMurayamaAKamamotoS, et al. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer J. 2022;12(4):54. doi:10.1038/s41408-022-00656-y.
16.
ZouG.A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-706. doi:10.1093/aje/kwh090.
17.
MurayamaAHirotaS.Industry payments to pathologists in the USA between 2013 and 2021. J Clin Pathol. 2023;76(8):566-570. doi:10.1136/jcp-2023-208901.
18.
CadiganNGChenJ.Properties of robust m-estimators for Poisson and negative binomial data. J Stat Comput Simul. 2001;70(3):273-288. doi:10.1080/00949650108812122.
19.
MurayamaA.Nine-year analysis of industry payments to geriatricians in the United States between 2014 and 2022 [published online ahead of print October 30, 2023]. J Am Med Dir Assoc. doi:10.1016/j.jamda.2023.09.025.
20.
MurayamaANakanoKKamamotoS, et al. Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the open payments database between 2014 and 2020. Clin Microbiol Infect. 2022;28(12):1655.e1-1655.e4. doi:10.1016/j.cmi.2022.07.023.
21.
MurayamaAKamamotoSSaitoHTanimotoTOzakiA.Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic. Ann Allergy Asthma Immunol. 2022;129(5):635-636. doi:10.1016/j.anai.2022.08.006.
22.
InoueKBlumenthalDMElashoffDTsugawaY.Association between physician characteristics and payments from industry in 2015-2017: observational study. BMJ Open. 2019;9(9):e031010. doi:10.1136/bmjopen-2019-031010.
23.
PutmanMSGoldsherJECrowsonCSDuarte-GarcíaA.Industry payments to practicing US rheumatologists, 2014-2019. Arthritis Rheumatol. 2021;73(11):2138-2144. doi:10.1002/art.41896.
24.
MurayamaAKamamotoSKugoHSaitoHOzakiA.Research and nonresearch industry payments to nephrologists in the United States between 2014 and 2021. J Am Soc Nephrol. 2023;34(10):1709-1720. doi:10.1681/ASN.0000000000000172.
25.
FengHWuPLegerM.Exploring the industry-dermatologist financial relationship: insight from the open payment data. JAMA Dermatol. 2016;152(12):1307-1313. doi:10.1001/jamadermatol.2016.3037.
26.
YingXRosenblattRFortuneBE.Trends in industry payments to gastroenterologists and hepatologists in the United States from 2014 to 2020. Gastroenterology. 2022;163(4):787-791. doi:10.1053/j.gastro.2022.06.029.
27.
MurayamaAKamamotoSHiguchiKShigetaHOzakiA.Trend in industry payments to rheumatologists in the United States during the COVID-19 pandemic between 2013 and 2021. J Rheumatol. 2023;50(4):575-577. doi:10.3899/jrheum.220512.
28.
AnnapureddyAMurugiahKMingesKEChuiPWDesaiNCurtisJP.Industry payments to cardiologists. Circ Cardiovasc Qual Outcomes. 2018;11(12):e005016. doi:10.1161/CIRCOUTCOMES.118.005016.
29.
MurayamaAKamamotoSShigetaHOzakiA.Industry payments during the COVID-19 pandemic to cardiologists in the United States. CJC Open. 2023;5(3):253-255. doi:10.1016/j.cjco.2023.01.001.
30.
AhlawatANarayanaswamiP.Financial relationships between neurologists and industry: the 2015 open payments database. Neurology. 2019;92(21):1006-1013. doi:10.1212/wnl.0000000000007640.
31.
MurayamaA.Evaluation of research and non-research industry payments to endocrinologists in the United States: an analysis of the open payments database from 2014 to 2022. Diabet Med. 2023:e15253. doi:10.1111/dme.15253.
32.
MurayamaA.A nine-year investigation of industry research and non-research payments to emergency physicians in the United States between 2014 and 2022 [published online ahead of print October 30, 2023]. J Emerg Med. doi:10.1016/j.jemermed.2023.10.026.
33.
DeJongCAguilarTTsengC-WLinGABoscardinWJDudleyRA.Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Intern Med. 2016;176(8):1114-1122. doi:10.1001/jamainternmed.2016.2765.
34.
PerlisRHPerlisCS.Physician payments from industry are associated with greater Medicare Part D prescribing costs. PLoS ONE. 2016;11(5):e0155474. doi:10.1371/journal.pone.0155474.
35.
HadlandSECerdáMLiYKriegerMSMarshallBDL. Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing. JAMA Intern Med. 2018;178(6):861-863. doi:10.1001/jamainternmed.2018.1999.
36.
HadlandSERivera-AguirreAMarshallBDLCerdáM.Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses. JAMA Netw Open. 2019;2(1):e186007. doi:10.1001/jamanetworkopen.2018.6007.
37.
AndersonTSKriegerMSMarshallBDLCerdáMHadlandS.Financial payments to teaching hospitals by companies marketing opioids. J Gen Intern Med. 2020;35(10):3108-3110. doi:10.1007/s11606-019-05596-1.
38.
HartungDMJohnstonKCohenDMNguyenTDeodharABourdetteDN.Industry payments to physician specialists who prescribe repository corticotropin. JAMA Netw Open. 2018;1(2):e180482. doi:10.1001/jamanetworkopen.2018.0482.
39.
MitchellAPTrivediNUGennarelliRL, et al. Are financial payments from the pharmaceutical industry associated with physician prescribing? a systematic review. Ann Intern Med. 2021;174(3):353-361. doi:10.7326/M20-5665.
40.
NgaageLMHarrisCGaoC, et al. Investigating the gender pay gap in industry contributions to academic neurosurgeons. World Neurosurg. 2019;130:516-522.e1. doi:10.1016/j.wneu.2019.06.145.
41.
FrintnerMPSiskBByrneBJFreedGLStarmerAJOlsonLM.Gender differences in earnings of early- and midcareer pediatricians. Pediatrics. 2019;144(4):e20183955. doi:10.1542/peds.2018-3955.
42.
Lo SassoATRichardsMRChouCFGerberSE.The $16,819 pay gap for newly trained physicians: the unexplained trend of men earning more than women. Health Aff (Millwood). 2011;30(2):193-201. doi:10.1377/hlthaff.2010.0597.
43.
StarmerAJFrintnerMPMatosKSombergCFreedGByrneBJ.Gender discrepancies related to pediatrician work-life balance and household responsibilities. Pediatrics. 2019;144(4):e20182926. doi:10.1542/peds.2018-2926.
44.
CamacciMLIkpohBLehmanEB, et al. Gender disparities among United States academic pediatric ophthalmologists: an analysis of publication productivity, academic rank, and NIH funding. J AAPOS. 2020;24(6):337.e1-337.e6. doi:10.1016/j.jaapos.2020.06.013.
45.
KimJLAllanJMFrommeHBForsterCSShaughnessyERalstonS.Gender distribution of scholarship and measures of national recognition in hospital medicine. Hosp Pediatr. 2022;12(2):117-124. doi:10.1542/hpeds.2021-006278.
46.
MarshallDCTarrasESRosenzweigKKorensteinDChimonasS.Trends in industry payments to physicians in the United States from 2014 to 2018. JAMA. 2020;324(17):1785-1788. doi:10.1001/jama.2020.11413.
47.
MurayamaA.Industry-sponsored meal payments are associated with prescriptions and Medicare expenditures on brand-name colchicine in the United States [published online ahead of print November 3, 2023]. Int J Rheum Dis. doi:10.1111/1756-185X.14962.
48.
MurayamaA.Pharmaceutical industry-sponsored meals and prescriptions of biologics for asthma. J Allergy Clin Immunol Pract. 2023;11(9):2916-2918. doi:10.1016/j.jaip.2023.05.030.
49.
MitchellAPDusetzinaSBMishra MezaATrivediNUBachPBWinnAN.Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study. BMJ. 2023;383:e075512. doi:10.1136/bmj-2023-075512.
50.
SunQWFormanHPRossJS.Industry payments and brand-name tyrosine kinase inhibitor use amid generic entry [published online ahead of print October 31, 2023]. Clin Trials. doi:10.1177/17407745231207971.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
